Trials / Active Not Recruiting
Active Not RecruitingNCT05953337
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- ABK Biomedical · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | EYE90 Microspheres Treatment | Y90 glass microspheres |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2023-07-20
- Last updated
- 2026-03-04
Locations
22 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05953337. Inclusion in this directory is not an endorsement.